Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics used adjunctively. Although this drug market is dominated by generic therapies, MDD patients’ heterogeneous response to current drugs and the need for additional efficacious therapies give branded agents (e.g., Trintellix, Rexulti, Vraylar, Spravato, Caplyta, and Auvelity) the opportunity to be incorporated into the treatment algorithm. In this highly competitive market, which blends generics with newer branded entrants, understanding realworld prescribing behavior is essential for drug developers and marketers. Our Treatment Algorithms study leverages national patientlevel claims data to examine the use of key therapies in newly diagnosed and recently treated MDD patients, offering a clear view of current treatment patterns and market dynamics.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
• How have Trintellix, Rexulti, Vraylar, Spravato, and Auvelity been integrated into the treatment algorithm, and what is their source of business?
• What percentage of MDD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of MDD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Key drugs covered

Trintellix, Rexulti, Vraylar, Spravato, Auvelity, sertraline, escitalopram, bupropion SR/XL, duloxetine

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Real-world data

U.S. pharmacy and medical claims data

Key analyses

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow